Trial reportAfrican health sciences2025
The efficacy of lactobacillus reuteri in conjunction with racecadotril in managing pediatric rotavirus enteritis and its impact on intestinal mucosa and immune function.
Trial report in African health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances in the Diagnosis and Treatment of Rotavirus Infections: Narrative Review.International journal of molecular sciences · 2025Review
- Innovations and African Health Sciences: telling it beyond our environs.African health sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to evaluate the effectiveness of combining Lactobacillus reuteri with racecadotril in treating pediatric rotavirus enteritis, focusing on its impact on intestinal mucosa and immune function. Methodology: Eighty-five children diagnosed with pediatric rotavirus enteritis were randomly divided into two groups: the control group (43 cases) receiving racecadotril alone and the observation group (42 cases) treated with both Lactobacillus reuteri and racecadotril. Evaluation of the RV conversion rate and treatment efficacy was conducted at 3d, 5d, and 7d post-treatment. The study also assessed changes in intestinal mucosal barrier function, immune response, and intestinal microbiota. Results: The observation group exhibited significantly higher RV conversion rates at 3d, 5d, and 7d post-treatment compared to the control group (P<0.05), reaching 61.90%, 76.19%, and 92.86%, respectively. Following treatment, the observation group showed improvements in mucosal barrier function, increased CD4+ levels, decreased AGEs, D-lactic acid, endotoxins, and CD8+ levels. There were notable changes in intestinal microbiota, with elevated Lactobacillus and Bifidobacterium levels and decreased Escherichia coli. Conclusions: Combining Lactobacillus reuteri and racecadotril in treating pediatric rotavirus enteritis demonstrated efficacy in regulating intestinal microbiota, alleviating mucosal barrier dysfunction, improving immune function, and enhancing treatment effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.